Literature DB >> 2847648

DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.

M Takahata1, T Nishino.   

Abstract

DNA gyrase from Staphylococcus aureus FDA 209P was partially purified by lysostaphin treatment, saturation with ammonium sulfate, and affinity chromatography on heparin-Sepharose and with a concentrator (Centricon 30). It was found to consist of two subunits: alpha and beta. The ability of new quinolone antibacterial agents such as norfloxacin, ofloxacin, and ciprofloxacin to inhibit DNA gyrase activity and cell growth was investigated. The inhibitory effects of the new quinolones against the activity of S. aureus DNA gyrase were in parallel with their antibacterial activities. The 50% inhibitory doses of norfloxacin, ofloxacin, and ciplofloxacin were 0.34, 0.31, and 0.24 micrograms/ml, respectively, while the 50% inhibitory doses of nalidixic acid and cinoxacin, which were less active against S. aureus FDA 209P, were 100 micrograms/ml or more.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847648      PMCID: PMC172375          DOI: 10.1128/AAC.32.8.1192

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  DNA gyrase: an enzyme that introduces superhelical turns into DNA.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; H A Nash
Journal:  Proc Natl Acad Sci U S A       Date:  1976-11       Impact factor: 11.205

4.  Purification and properties of an extracellular protease of Staphylococcus aureus.

Authors:  G R Drapeau; Y Boily; J Houmard
Journal:  J Biol Chem       Date:  1972-10-25       Impact factor: 5.157

5.  Bacillus subtilis DNA gyrase: purification of subunits and reconstitution of supercoiling activity.

Authors:  E Orr; W L Staudenbauer
Journal:  J Bacteriol       Date:  1982-07       Impact factor: 3.490

6.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

7.  Bacillus subtilis deoxyribonucleic acid gyrase.

Authors:  A Sugino; K F Bott
Journal:  J Bacteriol       Date:  1980-03       Impact factor: 3.490

8.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

9.  Micrococcus luteus DNA gyrase: active components and a model for its supercoiling of DNA.

Authors:  L F Liu; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

10.  DNA gyrase: affinity chromatography on novobiocin-Sepharose and catalytic properties.

Authors:  W L Staudenbauer; E Orr
Journal:  Nucleic Acids Res       Date:  1981-08-11       Impact factor: 16.971

View more
  15 in total

1.  Assessing sensitivity to antibacterial topoisomerase II inhibitors.

Authors:  Sonia K Morgan-Linnell; Hiroshi Hiasa; Lynn Zechiedrich; John L Nitiss
Journal:  Curr Protoc Pharmacol       Date:  2007-12

Review 2.  Biochemical characteristics and physiological significance of major DNA topoisomerases.

Authors:  J A Sutcliffe; T D Gootz; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Purification and properties of DNA gyrase from Vibrio cholerae.

Authors:  G Mukhopadhyay; A Ghosh
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

4.  Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; T Yamaguchi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

5.  Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.

Authors:  J Okuda; S Okamoto; M Takahata; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

6.  DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.

Authors:  A Y Saiki; L L Shen; C M Chen; J Baranowski; C G Lerner
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

7.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.

Authors:  N Nakanishi; S Yoshida; H Wakebe; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1991-06       Impact factor: 5.191

9.  A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus.

Authors:  M Trucksis; J S Wolfson; D C Hooper
Journal:  J Bacteriol       Date:  1991-09       Impact factor: 3.490

10.  Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.

Authors:  M Tanaka; K Sato; Y Kimura; I Hayakawa; Y Osada; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.